Industry News
Pharmaceutical Industry News
As Ekterly nears the one-year…
As Ekterly nears the one-year anniversary of its approval, Chiesi Group is making moves to acquire the rare disease med and its developer KalVista.
Patient groups’ perceptions of…
Patient groups’ perceptions of drugmakers with large U.S. footprints have shifted in the past year as the businesses have contended with political pressures, PatientView said.
With a new positive trial readout,…
With a new positive trial readout, the company is aiming to reach a broader set of patients with its multiple myeloma bispecific Elrexfio.
Novartis CEO Vas Narasimhan says…
Novartis CEO Vas Narasimhan says that Europe needs a “complete rethink” on how it prices its drugs, warning that the entrance of new pharmaceuticals into its markets could be delayed.
Pfizer now anticipates its…
Pfizer now anticipates its Vyndamax sales to remain “relatively stable” from 2028 through mid-2031, it said.
The FDA has told Amgen that…
The FDA has told Amgen that it is proposing to withdraw the approval of the rare disease drug Tavneos. The FDA cited new information that indicates that data was "manipulated" to facilitate the approval of Tavneos.
Rocket Pharmaceuticals has…
Rocket Pharmaceuticals has offloaded its lucrative FDA rare pediatric disease priority review voucher, striking a $180 million sale that reflects the high market demand for a speedy FDA review.
After breaking through the…
After breaking through the blockbuster sales threshold in 2025, AstraZeneca’s three-in-one inhaler Breztri Aerosphere has passed another crucial milestone as it chips in on the British drugmaker’s goal to reach revenues of $80 billion by
Haleon has kicked off a…
Haleon has kicked off a soccer-focused marketing campaign ahead of the FIFA World Cup coming to the U.S., putting midfielder Tyler Adams at the center of an ad about the support its products provide.
For the first time in its 16-year…
For the first time in its 16-year analysis of the pharma industry, Deloitte found obesity drugs are the largest contributor to late-stage pipeline value, overtaking longtime leader oncology.
Ahead of the July trial, a…
Ahead of the July trial, a Delaware court upheld GSK's Jemperli royalty obligations to AnaptysBio without any changes, dismissing the company's request to slash them by 50%.
Mundipharma and CorMedix have…
Mundipharma and CorMedix have announced a win for their antifungal drug Rezzayo at preventing invasive fungal diseases in patients receiving allogeneic hematopoietic stem cell transplants.
Eleventh-hour settlements with two…
Eleventh-hour settlements with two of the three generic drugmakers involved could bode well for both Pfizer and its ATTR competitor BridgeBio, analysts say.
Haleon, a healthcare consumer and…
Haleon, a healthcare consumer and OTC brand company, has hired Richard Manso, a Google veteran, as its new U.S. chief marketing officer.
Compared with a 5.3% increase in…
Compared with a 5.3% increase in Xtandi sales to $6 billion in fiscal year 2025, Astellas expects the star prostate cancer drug’s revenue to drop by 5.3% during fiscal 2026.
Already the largest biopharma…
Already the largest biopharma company in India, generics powerhouse Sun Pharma has doubled in size with its acquisition of women’s health leader Organon. With its $11.75 billion buyout, Sun has picked up a drugmaker that
After Xoma Royalty went on a…
After Xoma Royalty went on a dealmaking spree last year, the biotech royalty aggregator is now itself being bought out by its peer Ligand Pharmaceuticals.
The FDA has taken umbrage with…
The FDA has taken umbrage with certain Incyte promotional claims related to its chronic graft-versus-host disease treatment Niktimvo.
After recalibrating its production…
After recalibrating its production strategy in the late 2010s to help meet the realities of the CAR-T market, Gilead Sciences’ Kite Pharma is preparing to hit the ground running with the potential approval of a
The FDA rejected two new products…
The FDA rejected two new products from AbbVie and Grace Therapeutics, citing manufacturing-related concerns.